---
title: Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor
  hematopoietic cell transplantation
date: '2024-07-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39028876/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240720181330&v=2.18.0.post9+e462414
source: Blood
description: Abatacept plus calcineurin inhibitors/methotrexate (CNI/MTX) is the first
  FDA-approved regimen for acute graft-versus-host disease (aGVHD) prophylaxis during
  unrelated-donor hematopoietic cell transplantation (URD-HCT). We investigated its
  impact in URD-HCT patients using Center for International Blood and Marrow Transplant
  Research data for 7/8-human leukocyte antigen (HLA)-mismatched (MMUD) or 8/8-HLA-matched
  (MUD) URD-HCT recipients between 2011-2018. Primary outcomes included ...
disable_comments: true
---
Abatacept plus calcineurin inhibitors/methotrexate (CNI/MTX) is the first FDA-approved regimen for acute graft-versus-host disease (aGVHD) prophylaxis during unrelated-donor hematopoietic cell transplantation (URD-HCT). We investigated its impact in URD-HCT patients using Center for International Blood and Marrow Transplant Research data for 7/8-human leukocyte antigen (HLA)-mismatched (MMUD) or 8/8-HLA-matched (MUD) URD-HCT recipients between 2011-2018. Primary outcomes included ...